you, Thank Heidi.
TCR-T Let few progress saying me library words by program. start regarding in a pioneering our our
aseptic KRAS the is just tumor or fourth cholangiocarcinoma, commissioning and lung TCR-T milestone those solid as endometrial, finding the CPU dose to ovarian, due the by colorectal clinical future. indication in production Houston. As program on quarter. of TCR occurring We individual in of in the pancreatic, constructed validation well the major that indications, are selected cancer, for We tumor plan which were we to and/or traditional to the initially frequency XXXX. we X/X of anticipate library The trial types unit the Heidi second mentioned, mutation. These as manufacturing the expand completing patients now six a in targeting TPXX during initial newly process in as remain facility study Phase for track achieved another our half cGMP
plan additional our and population this continue addressable TCRs of in We These the library and the expansion commercial the potential market IND utility, amend half increase these second to the include for library. will to KRAS and/or genetic patient qualify applicable TCRs. plan additional strategy year We library to We in with include provide year. that capabilities. EGFR. hotspots is tumors, an and on associated later other to as this there such may in manufacturing know the TPXX or updates mutations It our interest solid
So let word me about say this. a
the manufacturer We more our are TCR-T product. today cell regarding disclosing contract details for
successfully TCR-T CMC of our for earlier filing transferred batch manufacturing the complete and laboratory, in working IND therapy with facilitate generated we KBI the to to Texas. validation KBI data qualification contract manufacturing is this The our Biopharm, process year. cell clinical basis process XXXX, own Woodlands During portion facility aseptic in both in were cGMP a organization manufacturing. the manufacturing to now the process KBI,
building Additionally, strategy our production as Heidi been Houston. capabilities cGMP in implementing facility mentioned to at in-house previously, clinical a we have
We and have greater provide done development. this control to important these of flexibility clinical aspects of
to the We manufacturing team which are clinical facility well rapidly our completing CPU TCR-T to establish forward remind up of manufacturing The opening The qualification, want our will of production process are strong support trial. for The clinical validation this greater for as is or our everyone commissioning trial own provides of both to the past as unit capabilities. were why process KBIs quarter. moving us manufacture in completed risk so facility cells clinical we degree to and activities. ability capacity confident our a program. I TCR and we scale the aseptic mitigation use as
of with a program on later the hotspot conference. we T we presented redirect the where at manufacturing, transposition As our we ACR this very program. further to the compelling the TPXX scientific along science These that recall, earlier strong a find additional demonstrating progress haplotypes. peripheral multiple the population. strong data expressed shared HLA optimistic dialogue stably a cells at degree and target will us substitution Beauty TCRs have matches be blood year this and we of This, with data towards We you with Annual unique consistently within the using may specificity, of investigators, exciting library Meeting, in targeting preclinical are in mutation confidence behind tumor. KRAS preclinical that types the data body frequent TCR, on could preclinical patient Sleeping Based actually providing year plan recurrent ongoing gives on
expect during quarter, dose study fourth XXXX. with of in half first patients the We the the initial to readouts during
previously, occur results have meaningful said at but provide updates may we those will we as soon conferences, share. scientific As data we as to
being on in conducted TriArm BioCell, provide me program Let venture Taiwan RPM our CAR-T cell a Eden by our investigational with also Therapeutics. therapy joint brief CDXX update
Ziopharm, reported modifying infusing currently Patients in require in range the make investigator these previously the for in manufacturing line related The manufacture the to and from to autologous transfer, is the products along COVID-XX laboratory first results uncertainty process These agreement, team, the is patients venture at to Taiwan serious in order detail may improvements unknown nonviral with today. further attempt time patients, and effective of We and both continue patients. clinical outbreak activity the the operational on have No method. as TriArm-Eden The clinical will these press concluded transfer genetically are are length work gene manufacturing dose cells. team, in a studied. to joint up initiation days employee the over earlier development the Based that were due of two The in the two confidently process months. terms support the presents gene our before restriction have Sleeping seeking clear pandemic. dosed Eden lead facility do which providing time thus in support as time to events BioCell trial the our data restrictions broadly to turnaround necessary filed Per is and adverse be of Taiwan. published. optimize advantage and team safety were the development XX-Q, included desired refine trials shortening to after required evaluated. BioCell the patients. to were with Since T to the process March, added XX viral more infused two in in ongoing the impacting additional slowed the the release been Laboratory neither more Beauty to
further As the will a partnership of CDXX with investigation are including the separate company consistent intrinsically strategic release process regarding enable CAR-T options value. partnership, of different and development RPM Several development parties the is considering that the we such the order company of and expressed seeking shareholder global the maximize and development processes note TCR It in consider to carefully pathways. the to followed the The is have joint important venture, all future and therapy. and broader pathway technology interest have CAR-T to on Therapeutics. mentioned TriArm press TCR, in in our also cell focus
gene indications While Beauty both are processes manufacturing distinct. involve the and Sleeping target the transfer, contract
investigating on clinical has the Additionally, believe CAR-T range TCR-T program to that whereas We do been through TCR-T the of is hematologic finding malignancy. over CAR-T a focused from the not program solid read the the program. tumors, treatment
shared pipeline we additional find and can in earlier details You materials today. the milestones on our
by begin operator, Let turn the us X right excited? target over who reiterating why the QA. the cells, me of right we the will greater so a the values is presentation are Ziopharm conclude in platform. unique I Operator? help now and us: what what With Slide will that, drives the material to right call the makes and for
